Cost-effectiveness of immune checkpoint inhibitors in nsclc according to pd-l1 expression

dc.creatorAguiar, Pedro, Jr. [UNIFESP]
dc.creatorPerry, Luke A.
dc.creatorLopes, Gilberto L., Jr.
dc.date.accessioned2019-01-21T10:29:40Z
dc.date.accessioned2022-10-07T20:43:17Z
dc.date.available2019-01-21T10:29:40Z
dc.date.available2022-10-07T20:43:17Z
dc.date.created2019-01-21T10:29:40Z
dc.date.issued2016
dc.identifierLung Cancer Management. London, v. 5, n. 3, p. 119-122, 2016.
dc.identifier1758-1966
dc.identifierhttp://repositorio.unifesp.br/handle/11600/49320
dc.identifier10.2217/lmt-2016-0016
dc.identifierWOS:000390431700001
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/4021808
dc.languageeng
dc.publisherHindawi Ltd
dc.relationLung Cancer Management
dc.rightsAcesso restrito
dc.subjectCost-Effectiveness
dc.subjectHealth Technology Assessment
dc.subjectImmunotherapy
dc.subjectLung CancerCell Lung-Cancer
dc.subjectPredictive Biomarker
dc.subjectMetaanalysis
dc.subjectNivolumab
dc.subjectDocetaxel
dc.subjectOutcomes
dc.titleCost-effectiveness of immune checkpoint inhibitors in nsclc according to pd-l1 expression
dc.typeEditorial


Este ítem pertenece a la siguiente institución